摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,6-二甲基异噁唑(5,4-B)吡啶-3-胺 | 916792-12-6

中文名称
4,6-二甲基异噁唑(5,4-B)吡啶-3-胺
中文别名
3-氨基-4,6-二甲基异噁唑[5,4-B]吡啶;4,6-二甲基异噁唑[5,4-B]吡啶-3-胺;4,6-二甲基异恶唑并[5,4-B]吡啶-3-胺
英文名称
4,6-dimethylisoxazolo[5,4-b]pyridin-3-amine
英文别名
4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-amine
4,6-二甲基异噁唑(5,4-B)吡啶-3-胺化学式
CAS
916792-12-6
化学式
C8H9N3O
mdl
——
分子量
163.179
InChiKey
DYMSNXTUZQZFSM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    338.6±37.0 °C(Predicted)
  • 密度:
    1.278±0.06 g/cm3(Predicted)
  • 稳定性/保质期:

    按规定使用和贮存的不会分解,避免与氧化物接触。

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    64.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2934999090

SDS

SDS:9eeeb6783532f8d0126d20af2d87ddbe
查看

文献信息

  • [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY<br/>[FR] INHIBITEURS DE TRYPTOPHANE DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE
    申请人:AUCKLAND UNISERVICES LTD
    公开号:WO2016024233A1
    公开(公告)日:2016-02-18
    Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    描述了包含具有IDO1和/or TDO抑制活性的3-氨基异恶唑啉化合物I的药物组合物,其中W是CR1,N或N-氧化物;X是CR2,N或N-氧化物;Y是CR3,N或N-氧化物;Z是CR4,N或N-氧化物;W、X、Y和Z中的至少一个是N或N-氧化物;R9和R10如所定义。还描述了使用这些化合物治疗各种疾病,如癌症的方法。
  • Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
    申请人:AUCKLAND UNISERVICES LIMITED
    公开号:US10888567B2
    公开(公告)日:2021-01-12
    Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    描述了包含具有 IDO1 和/或 TDO 抑制活性的式 I 的 3-异噁唑吡啶化合物的药物组合物,其中 W 是 CR1、N 或 N-氧化物;X 是 CR2、N 或 N-氧化物;Y 是 CR3、N 或 N-氧化物;Z 是 CR4、N 或 N-氧化物;W、X、Y 和 Z 中至少有一个是 N 或 N-氧化物;R9 和 R10 如所定义。 还描述了使用此类化合物治疗各种疾病(如癌症)的方法。
  • INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
    申请人:Auckland Uniservices Limited
    公开号:EP3180002A1
    公开(公告)日:2017-06-21
  • INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
    申请人:Palmer Brian Desmond
    公开号:US20170224701A1
    公开(公告)日:2017-08-10
    Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR 1 , N or N-oxide; X is CR 2 , N or N-oxide; Y is CR 3 , N or N-oxide; Z is CR 4 , N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R 9 and R 10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
查看更多

同类化合物

苯胺,4-肼基-3-甲氧基-N-苯基- 环丁[b][1,2]恶唑并[4,5-e]吡啶 异恶唑并[5,4-B]吡啶-3-胺 异噁唑并[5,4-c]吡啶-3-胺 异噁唑并[5,4-b]吡啶-3-醇 异噁唑并[4,5-b]吡啶-3-胺 异噁唑并[4,5-b]吡啶-3(2H)-酮 [1,2]恶唑并[5,4-e]吲嗪 9-氧杂-3-氮杂三环[5.2.1.03,8]癸-1,5,7-三烯 7H-[1,3]恶唑并[3,2-a]环氧乙烷并[d]吡啶 7-羟基-3-甲基[1,2]恶唑并[4,5-b]吡啶-5(4H)-酮 6-甲氧基-3-甲基[1,2]恶唑并[4,5-c]吡啶 6-(叔丁基)-3-甲基异噁唑并[5,4-B]吡啶-4-羧酸 5-肼基-3-甲基[1,2]恶唑并[4,5-b]吡啶 5-乙基-3-甲基[1,2]恶唑并[5,4-b]吡啶 5-乙基-3-甲基[1,2]恶唑并[4,5-b]吡啶 5,7-二氯-3-甲基异噁唑并[4,5-B]吡啶 4-甲氧基-3-甲基[1,2]恶唑并[5,4-b]吡啶 4-氧杂-7-氮杂三环[4.3.1.03,7]癸-1(9),2,5-三烯 4,6-二甲基异噁唑(5,4-B)吡啶-3-胺 3-甲基异噁唑并[5,4-b]吡啶 3-甲基[1,2]恶唑并[5,4-b]吡啶-5-甲酰氯 3-甲基[1,2]恶唑并[4,5-b]吡啶2-氧化物 3-甲基-6-噻吩-2-基异恶唑并[5,4-b]吡啶-4-羧酸 3-甲基-5H-异恶唑并[4,5-c]吡啶-4-酮 3-溴异噁唑并[5,4-B]吡啶 3-氨基异恶唑[4,5-C]并吡啶 3-(溴甲基)异噁唑并[5,4-B]吡啶 3-(1,3-苯并二恶唑-5-基)-N-[(1S)-1-苯乙基]-异唑并[5,4-c]吡啶-5-胺 3,6-二甲基[1,2]恶唑并[5,4-b]吡啶-4-醇 3,6-二甲基[1,2]恶唑并[5,4-b]吡啶 3,4-二甲基[1,2]恶唑并[5,4-b]吡啶-6(7H)-酮 2H-环戊二烯并[d]异噻唑并[5,4-b]吡啶(9CI) 2H-环戊二烯并[b][1,2]恶唑并[4,5-e]吡啶 2H-[1,2]恶唑并[5,4-b]吡咯并[3,4-D]吡啶 2-氯-N-异噁唑并[5,4-B]吡啶-3-基乙酰胺 1H-咪唑,1-丁基-2,5-二氢-2-(1-甲基乙基)- Methyl 3-cyclohexyloxy-6-cyclopropyl-[1,2]oxazolo[5,4-b]pyridine-4-carboxylate Prop-2-ynyl 6-cyclopropyl-3-methyl-[1,2]oxazolo[5,4-b]pyridine-4-carboxylate (S)-ethyl 2-(2-((3,5-dimethylisoxazol-4-yl)(hydroxy)methyl)furo[3,2-b]pyridin-5-yl)acetate (6-Chloropyridin-3-yl)methyl 6-cyclopropyl-3-methyl-[1,2]oxazolo[5,4-b]pyridine-4-carboxylate 5-Furyl-7-methyl-furo<2,3-c>pyridin 3-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]isoxazolo[4,5-e]pyridine 6-bromoisoxazolo[4,5-b]pyridin-3-amine 7-((S)-2-hydroxy-1-methyl-ethylamino)-[1,6]naphthyridine-2-carboxylic acid [(S)-(3-fluoro-phenyl)-(1-methyl-1H-pyrazol-4-yl)-methyl]-amide 7-bromo-3-(4-chloro-phenyl)-4-hydroxy-isoxazolo[5,4-c]pyridine-5-carboxylic acid ethyl ester 3-(4-methoxy-phenyl)-4-hydroxy-isoxazolo[5,4-c]pyridine-5-carboxylic acid ethyl ester 6-Cyclopropyl-3-methoxy-[1,2]oxazolo[5,4-b]pyridine-4-carboxylic acid Methanone, (3-amino-1-piperidinyl)[6-(2,5-dimethyl-3-thienyl)-3-methylisoxazolo[5,4-b]pyridin-4-yl]- 9-(4-Chloro-phenyl)-3-(3,4-dichloro-phenyl)-5-methyl-isoxazolo[4,5-e][1,2,4]triazolo[4,3-c]pyrimidine